Just In: Sprint Corp (NYSE:S), Bellerophon Therapeutics Inc (NASDAQ:BLPH)
Thinly traded nano cap Bellerophon Therapeutics Inc(NASDAQ:BLPH) is up 35% premarket on increased volume in response to its announcement that Belgian health authorities have approved the commencement of an open-label Phase 2 study assessing INOpulse for the treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease (PH-COPD). Patient recruiting (10 total) will start this quarter with results expected by year end.
INOpulse is a drug-device combination system that delivers pulsed doses of nitric oxide. It is portable, suitable for at-home use and automatically adjusts to the patient’s breathing patterns to deliver consistent dosing.
Sprint Corp(NYSE:S) Postpaid phone net additions of 173K mark the fourth straight quarter of net additions and the best FQ1 in nine years.
Postpaid phone churn of 1.39% improved Y/Y for the sixth straight quarter, is the lowest churn rate in company history.
Adjusted free cash flow of $466M grew $2.7B Y/Y. Total liquidity position of $11B, about half of that in cash, cash equivalents, and short-term investments.
Full-year fiscal 2016 outlook continues to be operating income of $1B-$1.5B; adjusted EBITDA of $9.5B-$10B; cash capital expenditures of about $3B; adjusted free cash flow around break-even.
Tags: Bellerophon Therapeutics Inc (NASDAQ:BLPH), Sprint Corp (NYSE:S)